Radiopharm Theranostics Ltd (RADX) Current Deferred Revenue (2025)
Radiopharm Theranostics (RADX) posted quarterly Current Deferred Revenue of $11019.0 for Q2 2025.
Radiopharm Theranostics Ltd (RADX) Current Deferred Revenue (2025) Analysis & Trends
Radiopharm Theranostics (RADX) has reported Current Deferred Revenue for 1 consecutive years, with $11019.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Current Deferred Revenue changed N/A year-over-year to $11019.0; the TTM figure through Jun 2025 stood at $11019.0 (changed N/A YoY), while the FY2025 annual figure was $11019.0, changed N/A from the prior year.
- Current Deferred Revenue was little changed at $11019.0 in Q2 2025 per RADX's latest filing.
- Across five years, Current Deferred Revenue topped out at $11019.0 in Q2 2025 and bottomed at $11019.0 in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 11,018.98 |